arrow
Ö

Özlem Kurt Azap

bas kent university
H指数:26
被引数:3,584

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rising antimicrobial resistance in urinary tract infections in Türkiye: an urgent need for update on regional treatment strategies and for enhanced antimicrobial stewardship efforts

土耳其尿路感染中不断上升的抗菌药物耐药性:亟需更新区域治疗策略并加强抗菌药物合理使用措施

2026-04-150
OAAI
Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Türkiye: A multi-centre retrospective matched-cohort study

比较他唑巴坦西他肟与其它适当抗菌疗法在治疗产OXA-48或KPC肠杆菌科细菌感染中的效果:一项多中心回顾性匹配队列研究(土耳其)。

2025-10-270
OAAI
Management of COVID-19 in Immunocompromised Patients: An ESCMID Consensus Document

免疫抑制患者中COVID-19的管理:ESCMID共识文件

2025-06-230
PRE
BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac
2023-07-124
OAAI
Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints

将EUCAST应用于CLSI断点,在产生NDM的克雷伯菌血流分离株中,头孢地洛尔耐药率较高

2023-06-305
OA
European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease

欧洲临床微生物学和传染病学会冠状病毒疾病指南2019: 轻/中度疾病患者治疗的更新

2022-12-0111
OA
Inappropriate use of ivermectin during the COVID-19 pandemic: primum non nocere!

新型冠状病毒肺炎大流行期间伊维菌素的不当使用: primum non nocere!

2022-07-017
OA
ESCMID COVID-19 living guidelines: drug treatment and clinical management: author's reply

ESCMID新型冠状病毒肺炎生活指南: 药物治疗和临床管理: 作者回复

2022-04-015
OA
Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting

携带耐碳青霉烯的克雷伯菌属的碳青霉烯酶的特征和结果。血流感染: OXA-48流行环境中的多中心前瞻性队列研究

2022-03-1731
PRE